<DOC>
	<DOCNO>NCT01198132</DOCNO>
	<brief_summary>The aim multicentre , randomise , double-blind , placebo-controlled study evaluate efficacy safety supplementary treatment cholecalciferol ( vitamin D3 ) subject relapse multiple sclerosis ( R MS ) treat subcutaneous ( s.c. ) interferon beta-1a 44 µg ( Rebif ) 3 time weekly . The subject divide 2 group , one receiving cholecalciferol 100,000 IU twice monthly along Rebif treatment group placebo along Rebif treatment . A total 200 subject recruit 20-30 centre France .</brief_summary>
	<brief_title>A Multicentre Study Efficacy Safety Supplementary Treatment With Cholecalciferol Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosis RRMS accord Poser criterion ( clinically definite multiple sclerosis [ CDMS ] laboratory support definite multiple sclerosis [ LSDMS ] ) accord McDonald criterion ( 2005 ) . Subjects age 18 65 year . Treated interferon beta1a 44 µg ( 22 µg case intolerance 44 µg ) 3 time weekly subcutaneously 4 month ± ( 2 month ) randomization visit ( V1 ) . Expanded disability status scale ( EDSS ) score 0 5 . At least one document episode last two year . Stable disease episode last 30 day . Serum 25hydroxyvitamin D &lt; 75 nmol/l randomization visit . Women must pregnant breastfeeding , woman childbearing age must meet following criterion : Surgically sterilise , Using highly effective contraceptive method throughout entire duration study . A highly effective contraceptive method define method low failure rate ( i.e . &lt; 1 % per year ) regular appropriate use , e.g . implant , injectable contraceptive , combine oral contraceptive , coil , abstinence vasectomise partner . Menopausal woman may include . Affiliated French healthcare insurance . Subjects must ready able provide inform consent comply protocol requirement . Hormonal abnormality associate vitamin D low dietary intake reduce exposure sun , example malabsorption ( coeliac disease , Whipple 's disease , inflammatory bowel disease , intestinal derivation , short bowel syndrome ) , cirrhosis , nephrotic syndrome , hyperthyroidism , rickets , hypoparathyreosis , cancer , granulomatous disease ( sarcoidosis , silicosis ) lymphomas know initial visit . Patients osteoporosis know osteopenia . Use medicine affect vitamin D metabolism corticosteroid , e.g . anticonvulsant ( phenobarbital , primidone , phenytoin ) , rifampicin , isoniazid , ketoconazole , 5FU leucovorin , thiazide diuretic . Previous ongoing hypercalcaemia . Situations involve increased susceptibility hypercalcaemia , e.g . know cardiac arrhythmia cardiac disease , treatment digitalis , renal lithiasis . Any contraindication treatment ( cholecalciferol ) state summary product characteristic . Moderate renal impairment define creatinine clearance 30 60 ml/min . An active episode month prior inclusion study . Inadequate liver function , define total bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase &gt; 2.5 * upper limit normal . Severe renal impairment define creatinine clearance 30 ml/min . Inadequate marrow reserve , define white blood cell &lt; 0.5 * low limit normal . Serious acute heart disease uncontrolled cardiac arrhythmia , uncontrolled angina , cardiomyopathy uncontrolled congestive heart failure . History severe depression , attempt suicide ongoing suicidal ideation . Epilepsy inadequately control treatment . Ongoing previous alcohol drug abuse ( within last two year ) . Major medical psychiatric disease , opinion investigator , would place subject risk could adversely affect compliance study protocol . Known hypersensitivity gadolinium and/or know inability undergo MRI . Any medical condition require chronic treatment systemic corticosteroid . Participation study involve study product 30 day prior inclusion study . Legal incapacity limit legal capacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Multiple Sclerosis Relapsing-Remitting</keyword>
	<keyword>Relapsing Multiple Sclerosis ( RMS )</keyword>
	<keyword>Rebif</keyword>
	<keyword>Vitamin D3</keyword>
	<keyword>Cholecalciferol</keyword>
</DOC>